📅 PUBMED DAILY TRIAGE — 2026-04-21

Window: 2026-04-20T09:00Z → 2026-04-21T09:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~100 candidates | Candidates evaluated: ~100 High priority: 6 | Standard: 12 | Low/archive: 5 | Unsolicited finds: 0 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Early Cancer Detection (Liquid Biopsy / ctDNA / cfDNA)

• TR-2026-04-21-001 · [PMID 42006277] · Mutation-Specific Response to Ramucirumab in EGFR-Mutated Metastatic NSCLC: Insights From cfDNA Profiling (Liquid Biopsy Addendum of RELAY Phase 3) · 8/10 · 🔴 EARLY_CANCER_DETECTION — Phase 3 RCT addendum shows cfDNA profiling enables mutation-specific treatment stratification in EGFR NSCLC, translating liquid biopsy directly into a validated Phase 3 setting. (JTO Clin Res Rep, Nishio K et al.)
• TR-2026-04-21-002 · [PMID 42007449] · Whole-genome sequencing of cfDNA for MRD assessment in high-risk smoldering multiple myeloma · 8/10 · 🔴 EARLY_CANCER_DETECTION — WGS-based cfDNA enables non-invasive MRD monitoring in smoldering MM before overt disease, directly addressing a critical clinical gap. (HemaSphere, Baker C et al.)

Hematologic Malignancies (AML/MDS/CLL/MPN/Lymphoma)

(Best hematologic malignancy HIGH: see liquid biopsy section — PMID 42007449 is cross-topical)

CBC-Based Diagnostics and ML in Hematology

• TR-2026-04-21-003 · [PMID 42007253] · Artificial intelligence-based prognostic models in acute myeloid leukemia: systematic review and meta-analysis · 8/10 · 🟠 NOVEL_TREATMENT — SR/MA consolidates highest-level evidence that AI models outperform conventional AML prognostics; CBC/ML 14-day drought broken. (Blood Neoplasia, Zhang X et al.)
• TR-2026-04-21-004 · [PMID 42006429] · Hematologic biomarkers of aging (HemeAge) and cardiovascular risk: a machine learning analysis in two cohorts · 8/10 · 🟢 NEAR_TERM_IMPLEMENTABLE — CBC-derived ML aging score validated in two cohorts predicts CVD risk from routine blood tests; dual relevance to CBC/ML and cardiometabolic watchlists. (Am J Prev Cardiol, Siddharth A et al.) ⚠️ Alert suppressed (5-per-run cap).

Cardiovascular-Metabolic (GLP-1 / SGLT2 / Cardiometabolic)

• TR-2026-04-21-005 · [PMID 42007145] · Impact of SGLT-2 inhibitors on long-term prognosis in HFpEF: SR/MA of RCTs · 8/10 · 🟢 NEAR_TERM_IMPLEMENTABLE — Highest-tier evidence confirms SGLT-2 inhibitors significantly improve long-term outcomes in HFpEF, a phenotype with historically limited proven therapies. (Am J Transl Res, Shi P & Chen T)
• TR-2026-04-21-006 · [PMID 42007544] · Tirzepatide as Adjunct to Insulin in Adults With Type 1 Diabetes and Overweight or Obesity: SR of Randomized and Real-World Evidence · 8/10 · 🟠 NOVEL_TREATMENT — First SR combining RCT + real-world evidence for tirzepatide in T1D+obesity, an underserved population with no licensed GLP-1/GIP dual agonist option. (Endocrinol Diabetes Metab, Acucella GA & Caponio D)

Topics with Zero 8+ Articles Today:

• Precision oncology/genomic medicine: No HIGH articles (best: PMID 42006875, 6/10)
• Novel therapeutics (immunotherapy/CAR-T/targeted therapy): No stand-alone HIGH (PMID 42007544 cross-topical)
• Aging, longevity, and population health: No HIGH articles (best: PMID 42007503, 7/10)
• Rare diseases with high unmet need: No HIGH articles (best: PMID 42007479, 5/10)
• Sentinel scan: No unsolicited finds qualifying above STANDARD

🟢⚪ STANDARD (5-7) — Top by Topic

Hematologic Malignancies

• TR-2026-04-21-007 · [PMID 42007444] · APL-like subset within NPM1-mutated AML correlating with early vascular complications · 7/10 · Diagnostics (HemaSphere, Mannelli F et al.)
• TR-2026-04-21-010 · [PMID 42007446] · IntegrateALL: end-to-end RNA-seq pipeline for B-precursor ALL subtype classification · 7/10 · Diagnostics/AI (HemaSphere, Wolgast N et al.)
• TR-2026-04-21-011 · [PMID 42007448] · Biological and clinical characteristics of ETV6::RUNX1-like ALL · 6/10 · Genomics/Precision Medicine (HemaSphere, Zaliova M et al.)
• TR-2026-04-21-014 · [PMID 42007609] · Exportin 1 inhibitor + Venetoclax induces apoptosis in MDS via mitochondrial pathway · 5/10 · Drug Development [preclinical cap] (J Clin Lab Anal, Liu X et al.)
• TR-2026-04-21-015 · [PMID 42007255] · Targeting GPER: novel therapeutic strategy in cutaneous T-cell lymphoma · 5/10 · Drug Development [preclinical cap] (Blood Neoplasia, Özistanbullu D et al.)

Early Cancer Detection / Liquid Biopsy

• TR-2026-04-21-008 · [PMID 42006774] · Cell-free chromatin epigenomic profiling enables non-invasive pancreatic cancer cell-state identification · 7/10 · Early Detection [PREPRINT — capped] (medRxiv, Semaan K et al.)

CBC/ML Hematology

• TR-2026-04-21-013 · [PMID 42006310] · Interpretable neural network for risk stratification and drug target discovery from PBMC transcriptomes · 6/10 · Diagnostics (iScience, Yu Z et al.)

Precision Oncology / Genomics

• TR-2026-04-21-012 · [PMID 42006875] · NTRK fusions + immune/genomic landscape by comprehensive DNA/RNA profiling in a large healthcare system · 6/10 · Genomics/Precision Medicine (Front Med, Dowdell AK et al.)

Cardiovascular-Metabolic

• TR-2026-04-21-016 · [PMID 42006939] · GLP-1 receptor agonists in acute ischemic stroke and secondary prevention: narrative review · 5/10 · Treatment Innovation (J Cent Nerv Syst Dis, Samanidou V et al.)

Aging / Population Health

• TR-2026-04-21-009 · [PMID 42007503] · Body composition and physical function with incident diabetes in older adults: 14-year prospective cohort · 7/10 · Prevention (J Cachexia Sarcopenia Muscle, Zhang T et al.)
• TR-2026-04-21-018 · [PMID 42007221] · Upper GI cancers global burden, trends, and life expectancy impact 1990-2021 · 5/10 · Public Health (J Natl Cancer Cent, Teng Y et al.)

Rare Diseases

• TR-2026-04-21-017 · [PMID 42007479] · Automating evaluation of LLM-generated responses to rare disease patient questions · 5/10 · Diagnostics/AI (JAMIA Open, Zhao M et al.)

💡 UNSOLICITED FINDS

None — all scored articles matched active watchlist topics.

Sentinel scan (n=372 raw results, 10 reviewed): top candidates all mapped to existing watchlist topics or scored <5. PMIDs 42009662, 42009577, 42008449, 42008246 deferred to 2026-04-22 run.

📊 TODAY'S BREAKDOWN

By research category:

• Diagnostics: 6
• Treatment Innovation: 5
• Early Detection: 3
• Drug Development: 2
• Genomics/Precision Medicine: 2
• Prevention: 2 (shared with other categories above)
• Public Health: 1

By evidence maturity:

• Validated: 10
• Exploratory: 7
• Potentially Practice-Changing: 2 (PMID 42006277, 42007145)

By watchlist topic (reviewed / kept ≥5 / highest score):

By source type:

• Peer reviewed: 17
• Preprint: 1 (PMID 42006774, medRxiv)

Topics with zero 8+ articles this run: Precision oncology, Aging/longevity, Rare diseases, Sentinel scan

🔧 RUN NOTES

• Window expansion: Not triggered (≥5 relevant articles found in primary 24h window)
• Truncation: Flagged for AI/ML (160 raw, 10 reviewed) and Novel therapeutics (106 raw, 10 reviewed) and Sentinel (372 raw, 10 reviewed)
• CBC/ML hematology drought: 14-consecutive-day drought BROKEN — 17 articles found; 2 scored HIGH (PMID 42007253 and 42006429). Both articles independently validated across published literature.
• Alert cap: 6 HIGH articles identified; alert cap of 5 applied. PMID 42006429 (HemeAge, score 8) included in JSON but alert suppressed.
• GLP-1/SGLT2 recovery: Topic returned 46 articles after prior-day drought.
• PMC access: 15 of 18 articles have PMC full text available; 2 are abstract-only; 1 preprint with PMC.
• Deferred PMIDs: 42009662, 42009577, 42008449, 42008246 from sentinel scan carried to 2026-04-22.
• Rolling 7-day zero-HIGH topics: Precision oncology (3+ days), Aging/longevity (5+ days), Rare diseases (7+ days). CBC/ML drought now resolved.